Announced: May 2008Headquarters: Laramie, WY
Chief Executive Officer: Glenn Cornett
Chief Operating Officer: Jim Page
Board of Directors: Glenn Cornett, Jim Page, Karen Page
Navitas is a privately-held pharmaceutical company focused on the development of novel treatments for cardiovascular and metabolic diseases with a focus on compounds that act via enhanced coupling of endothelial nitric oxide synthase (eNOS). Navitas’ lead product is cicletanine, an oral, once-daily agent that is approved in certain European countries for the treatment of hypertension and is currently being evaluated for the treatment of pulmonary arterial hypertension in the United States. Acting as exclusive financial advisor, Torreya ran a sale process involving multiple bidders which resulted in the acquisition of the company by Gilead, a large biopharmaceutical company focusing on areas of unmet medical need including infectious diseases and pulmonary diseases. A term sheet was received after one month of engagement by Navitas. At the time of retention there were no parties at the table. Navitas currently operates as a subsidiary of Gilead.
Copyright © 2010 Torreya Partners LLC. All rights reserved.
Securities offered through Financial West Group, member FINRA/SIPC. Torreya Partners LLC and Financial West Group are unaffiliated entities.